The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma. 2001

H Utsunomiya, and T Suzuki, and C Kaneko, and J Takeyama, and J Nakamura, and K Kimura, and M Yoshihama, and N Harada, and K Ito, and R Konno, and S Sato, and K Okamura, and H Sasano
Departments of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai 980-8574. H-Utsu@ob-gy.med.tohoku.ac.jp

Intratumoral metabolism and synthesis of estrogens are considered to play very important roles in the pathogenesis and development of human endometrial adenocarcinoma. The 17beta-hydroxysteroid dehydrogenase (17beta-HSD) isozymes catalyze the interconversion of estradiol (E2) and estrone and thereby serve to modulate the tissue levels of bioactive E2. To elucidate the possible involvement of this enzyme in human endometrial carcinoma, we first examined the expression of 17beta-HSD type 1 and type 2 in 20 normal cycling human endometria, 36 endometrial hyperplasia, and 46 endometrial endometrioid adenocarcinoma using immunohistochemistry, and we then studied immunoreactivity of 17beta-HSD type 2 using immunoblotting analyses, the activity of 17beta-HSD type 1 and type 2 using thin-layer chromatography and their expression using RT-PCR in endometrial endometrioid adenocarcinoma. We correlated these findings with various clinicopathological parameters to examine the biological significance of 17beta-HSDs in human endometrial disorders. 17beta-HSD type 2 immunoreactivity in normal endometrium was present in all cases of secretory phase (n = 14), but not in any endometrial mucosa of proliferative phase (n = 6). In addition, 17beta-HSD type 2 immunoreactivity was detected in 27 of 36 (75%) endometrial hyperplasia and 17 of 46 (37%) carcinoma cases. 17beta-HSD type 1 immunoreactivity was not detected in all the cases examined. In both endometrial hyperplasia and carcinoma cases there were significant positive correlations between 17beta-HSD type 2 and progesterone receptor labeling index (LI). In carcinoma cases, a significant inverse correlation was detected between 17beta-HSD type 2 immunoreactivity and age. In addition, 17beta-HSD type 2 immunoreactivity was also correlated with 17beta-HSD type 2 enzymatic activity, and semiquantitative analyses of 17beta-HSD type 2 messenger RNA. No significant correlations were detected between 17beta-HSD type 2 and estrogen receptor LI, Ki67 LI, amount of aromatase messenger RNA or histological grade. These data indicated that the expression of 17beta-HSD type 2 in hyperplastic and/or neoplastic endometrium may represent altered cellular features through hyperplastic and neoplastic transformation. However, 17beta-HSD type 2 may also play some protective and/or suppressive roles toward unopposed estrogenic effects through inactivating E2 in situ, especially in premenopausal patients.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D008597 Menstrual Cycle The period from onset of one menstrual bleeding (MENSTRUATION) to the next in an ovulating woman or female primate. The menstrual cycle is regulated by endocrine interactions of the HYPOTHALAMUS; the PITUITARY GLAND; the ovaries; and the genital tract. The menstrual cycle is divided by OVULATION into two phases. Based on the endocrine status of the OVARY, there is a FOLLICULAR PHASE and a LUTEAL PHASE. Based on the response in the ENDOMETRIUM, the menstrual cycle is divided into a proliferative and a secretory phase. Endometrial Cycle,Ovarian Cycle,Cycle, Endometrial,Cycle, Menstrual,Cycle, Ovarian,Cycles, Endometrial,Cycles, Menstrual,Cycles, Ovarian,Endometrial Cycles,Menstrual Cycles,Ovarian Cycles
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D004714 Endometrial Hyperplasia Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant. Atypical Endometrial Hyperplasia,Complex Endometrial Hyperplasia,Simple Endometrial Hyperplasia,Atypical Endometrial Hyperplasias,Complex Endometrial Hyperplasias,Endometrial Hyperplasia, Atypical,Endometrial Hyperplasia, Complex,Endometrial Hyperplasia, Simple,Endometrial Hyperplasias,Endometrial Hyperplasias, Atypical,Endometrial Hyperplasias, Complex,Endometrial Hyperplasias, Simple,Hyperplasia, Atypical Endometrial,Hyperplasia, Complex Endometrial,Hyperplasia, Endometrial,Hyperplasia, Simple Endometrial,Hyperplasias, Atypical Endometrial,Hyperplasias, Complex Endometrial,Hyperplasias, Endometrial,Hyperplasias, Simple Endometrial,Simple Endometrial Hyperplasias
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D015067 17-Hydroxysteroid Dehydrogenases A class of enzymes that catalyzes the oxidation of 17-hydroxysteroids to 17-ketosteroids. EC 1.1.-. 17 beta-Hydroxysteroid Dehydrogenases,Testosterone Dehydrogenases,17-Ketosteroid Reductases,17 Hydroxysteroid Dehydrogenases,17 Ketosteroid Reductases,17 beta Hydroxysteroid Dehydrogenases,Dehydrogenases, 17 beta-Hydroxysteroid,Dehydrogenases, 17-Hydroxysteroid,Dehydrogenases, Testosterone,Reductases, 17-Ketosteroid

Related Publications

H Utsunomiya, and T Suzuki, and C Kaneko, and J Takeyama, and J Nakamura, and K Kimura, and M Yoshihama, and N Harada, and K Ito, and R Konno, and S Sato, and K Okamura, and H Sasano
May 1975, Acta endocrinologica,
H Utsunomiya, and T Suzuki, and C Kaneko, and J Takeyama, and J Nakamura, and K Kimura, and M Yoshihama, and N Harada, and K Ito, and R Konno, and S Sato, and K Okamura, and H Sasano
July 2010, International journal of clinical and experimental pathology,
H Utsunomiya, and T Suzuki, and C Kaneko, and J Takeyama, and J Nakamura, and K Kimura, and M Yoshihama, and N Harada, and K Ito, and R Konno, and S Sato, and K Okamura, and H Sasano
February 2005, The Journal of steroid biochemistry and molecular biology,
H Utsunomiya, and T Suzuki, and C Kaneko, and J Takeyama, and J Nakamura, and K Kimura, and M Yoshihama, and N Harada, and K Ito, and R Konno, and S Sato, and K Okamura, and H Sasano
January 1976, Journal of steroid biochemistry,
H Utsunomiya, and T Suzuki, and C Kaneko, and J Takeyama, and J Nakamura, and K Kimura, and M Yoshihama, and N Harada, and K Ito, and R Konno, and S Sato, and K Okamura, and H Sasano
March 2010, The American journal of pathology,
H Utsunomiya, and T Suzuki, and C Kaneko, and J Takeyama, and J Nakamura, and K Kimura, and M Yoshihama, and N Harada, and K Ito, and R Konno, and S Sato, and K Okamura, and H Sasano
October 1975, The Journal of endocrinology,
H Utsunomiya, and T Suzuki, and C Kaneko, and J Takeyama, and J Nakamura, and K Kimura, and M Yoshihama, and N Harada, and K Ito, and R Konno, and S Sato, and K Okamura, and H Sasano
April 1997, The Journal of steroid biochemistry and molecular biology,
H Utsunomiya, and T Suzuki, and C Kaneko, and J Takeyama, and J Nakamura, and K Kimura, and M Yoshihama, and N Harada, and K Ito, and R Konno, and S Sato, and K Okamura, and H Sasano
November 2003, The Journal of steroid biochemistry and molecular biology,
H Utsunomiya, and T Suzuki, and C Kaneko, and J Takeyama, and J Nakamura, and K Kimura, and M Yoshihama, and N Harada, and K Ito, and R Konno, and S Sato, and K Okamura, and H Sasano
May 1975, Acta endocrinologica,
H Utsunomiya, and T Suzuki, and C Kaneko, and J Takeyama, and J Nakamura, and K Kimura, and M Yoshihama, and N Harada, and K Ito, and R Konno, and S Sato, and K Okamura, and H Sasano
June 2006, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!